| Patent Number |
Title Of Patent |
Date Issued |
| 7335370 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
February 26, 2008 |
| The present invention provides a method of immunizing a host against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method involves nucleic acid immunization, including DNA immunization, and employs a vector containing a nucleotide sequence which |
| 7241449 |
Transferrin receptor genes of moraxella |
July 10, 2007 |
| Purified and isolated nucleic acid molecules are provided which encode Tbp2 proteins of M. catarrhalis strains M35, 3 and LES1. The nucleic acid sequence may be used to produce recombinant Tbp2 proteins of the strain of Moraxella free of other proteins of the Moraxella strain for purpose |
| 7015033 |
Co-expression of recombination proteins |
March 21, 2006 |
| Expression vectors are described which permit the recombinant expression of proteins which essentially contain, in addition to nucleic acid encoding the recombinant protein, nucleic acid encoding a non-proteolytic analog of Haemophilus Hin47 protein, with or without leader sequence, or |
| 7008784 |
Non-infectious, non-replicating, immunogenic human immunodeficiency virus-like particles |
March 7, 2006 |
| The present invention is directed toward methods for the production of non-infectious, replication-deficient, immunogenic human immunodeficiency virus (HIV)-like particles. These particles are prepared from a recombinant expression vector comprising a heterologous promoter operativel |
| 6974581 |
Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect |
December 13, 2005 |
| A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae. Such composition comprises at least two different antigens of Haemophilus influenzae, one of which is an adhesin. High molecular weight (HMW) proteins |
| 6872814 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
March 29, 2005 |
| In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence |
| 6855537 |
Macrophage-infecting parasites expressing a granulocyte macrophage colony stimulated factor |
February 15, 2005 |
| Strains of Leishmania and other macrophage-infecting parasites are provided which express the GM-CSF gene which are useful in treating hosts infected by the parasite and in protecting hosts against disease caused by infection of hosts by parasites. The parasites are reduced in their |
| 6849447 |
Protective recombinant Haemophilus influenzae high molecular weight proteins |
February 1, 2005 |
| Protective high molecular weight (HMW) proteins are produced recombinantly by expression from E. coli by using a promoter effective in E. coli and a nucleic acid molecule which contains a modified operon of a non-typeable strain of Haemophilus. The modified operon contains the portion on |
| 6811783 |
Immunogenic compositions for protection against chlamydial infection |
November 2, 2004 |
| A protective immune response against Chlamydial infection is achieved by in vivo administration of an immunogenic composition comprising two vectors and a pharmaceutically-acceptable carrier therefor. One of the vectors comprises a first nucleotide sequence encoding a major outer membran |
| 6808713 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
October 26, 2004 |
| The present invention provides a method of immunizing a host against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method involves nucleic acid immunization, including DNA immunization, and employs a vector containing a nucleotide sequence which |
| 6764682 |
Adjuvant compositions containing more than one adjuvant |
July 20, 2004 |
| Adjuvant compositions for modulating an immune response to an antigen administered to a host comprise a mineral salt adjuvant and at least one other adjuvant. The compositions provide an adjuvanting effect on an antigen which is greater than the adjuvanting effect attainable by one of |
| 6693087 |
Nucleic acid molecules encoding POMP91A protein of Chlamydia |
February 17, 2004 |
| An isolated and purified nucleic acid molecule encoding a POMP91A protein of a strain of Chlamydia, is useful for nucleic acid immunization of a host, including a human host, against disease caused by infection by a strain of Chlamydia, particularly C. pneumoniae. |
| 6686339 |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
February 3, 2004 |
| In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence |
| 6677127 |
Nucleic acid respiratory syncytial virus vaccines |
January 13, 2004 |
| Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F prot |
| 6676949 |
Two-step immunization procedure against Chlamydia infection |
January 13, 2004 |
| A host is immunized against infection by a strain of Chlamydia by initial administration of an attenuated bacteria harbouring a nucleic acid encoding a Chlamydia protein followed by administration of a Chlamydia protein in ISCOMs. This procedure enables a high level of protection to be |
| 6660275 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
December 9, 2003 |
| The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a CPN100605 polype |
| 6656472 |
Multi oligosaccharide glycoconjugate bacterial meningitis vaccines |
December 2, 2003 |
| Multivalent immunogenic molecules comprise a carrier molecule containing at least one functional T-cell epitope and multiple different carbonhydrate fragments each linked to the carrier molecule and each containing at least one functional B-cell epitope. The carrier molecule inparts enha |
| 6649370 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
November 18, 2003 |
| In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence |
| 6642025 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
November 4, 2003 |
| In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence |
| 6635746 |
Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and method |
October 21, 2003 |
| Immunogenic compositions including vaccines are described that comprise an outer membrane antigen extract of a strain of Chlamydia and are effective in protection against disease caused by Chlamydia infection The immunogenic compositions may comprise the major outer membrane protein |
| 6632663 |
DNA immunization against chlamydia infection |
October 14, 2003 |
| Nucleic acid, including DNA, immunization is used to generate a protective immune response in a host, including humans, to a serine-threonine kinase (STK) of a strain of Chlamydia. A non-replicating vector, including a plasmid vector, contains a nucleotide sequence encoding a STK or a |
| 6623764 |
Biodegradable targetable microparticle delivery system |
September 23, 2003 |
| Copolymers designed for use as particulate carriers containing functionalizable amino acid subunits for coupling with targeting ligands are described. The copolymers are polyesters composed of .alpha.-hydroxy acid subunits such as D,L-lactide and pseudo-.alpha.-amino acid subunits wh |
| 6572863 |
Constitutive expression of non-infectious HIV-like particles |
June 3, 2003 |
| Non-infectious, non-replicating immunogenic HIV-like particles are produced by stable long-term constitutive expression in mammalian cells by eliminating elements toxic to the mammalian cells. An expression vector contains a nucleic acid molecule comprising a modified HIV genome devoid |
| 6548070 |
Attenuated strains of mycobacteria |
April 15, 2003 |
| Attenuated strains of Mycobacterium, particularly species of the tuberculosis complex, have the mycobacterial cell entry (mce) gene functionally disabled. The gene may be disabled by an insertion into the gene which disrupts the mycobacterial cell entry function thereof of a selectab |
| 6544752 |
Anigenically-marked non-infectious retrovirus-like particles |
April 8, 2003 |
| Non-infectious, retrovirus-like particles comprise an assembly of an env gene product, a pol gene product and a gag gene product contain an antigenic marker which is non-retroviral or non-HIV retroviral. In one embodiment, the marker comprises an amino acid sequence containing an epi |
| 6544527 |
Non-infectious, immunogenic, human immunodeficiency virus-like particles devoid of long terminal |
April 8, 2003 |
| Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene product and eliminate RNase H activity of the pol |
| 6541250 |
Continuous adherent melanocyte cell line |
April 1, 2003 |
| The present invention comprises a novel immortal non-adherent human melanocyte cell line, designated WC-1 14.07. This cell line is stable and MHC class I negative. This continuous melanocyte cell line can be used as a source of melanin and hgp100. The Class I MHC-negative nature of this |
| 6521745 |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
February 18, 2003 |
| An isolated and purified nucleic acid molecule encoding an inclusion membrane protein C of a strain of Chlamydia, is useful for nucleic acid immunization of a host, including a human host, against disease caused by infection by a strain of Chlamydia, particularly C. pneumoniae. |
| 6518030 |
Antigentically-marked non-infectious retrovirus-like particles |
February 11, 2003 |
| Non-infectious, retrovirus-like particles comprise an assembly of an env gene product, a pol gene product and a gag gene product contain an antigenic marker which is non-retroviral or non-HIV retroviral. In one embodiment, the marker comprises an amino acid sequence containing an epi |
| 6503514 |
Attenuated strains of mycobacteria |
January 7, 2003 |
| Attenuated strains of Mycobacterium, particularly species of the tuberculosis complex, have the mycobacterial cell entry (mce) gene functionally disabled. The gene may be disabled by an insertion into the gene which disrupts the mycobacterial cell entry function thereof of a selectab |
| 6486135 |
Nucleic acid respiratory syncytial virus vaccines |
November 26, 2002 |
| Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may l |
| 6475780 |
Alphavirus vectors for paramyxovirus vaccines |
November 5, 2002 |
| A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory sync |
| 6471996 |
Biodegradable targetable microparticle delivery system |
October 29, 2002 |
| Copolymers designed for use as particulate carriers containing functionalizable amino acid subunits for coupling with targeting ligand are described. The copolymers are polyesters composed of .alpha.-hydroxy acid subunits such as D,L-lactide and .alpha.-amino acid subunits such as se |
| 6464979 |
Chlamydial vaccines and methods of preparation thereof |
October 15, 2002 |
| Immunogenic compositions including vaccines are described that comprise an outer membrane antigen extract of a strain of Chlamydia and are effective in protection against disease caused by Chlamydia infection. The immunogenic compositions may comprise the major outer membrane protein |
| 6455050 |
Production of virus and purfication of viral envelope proteins for vaccine use |
September 24, 2002 |
| Immunogenic envelope glycoproteins are produced from enveloped virus, such as of the paramyxoviridae family, particularly PIV-3 and RSV, by culturing the virus in the substantial absence of exogenous serum proteins, isolating the virus from the tissue culture, solubilizing the envelope |
| 6451322 |
Retrovirus like particles made non infectious by a plurality of mutations |
September 17, 2002 |
| Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene, product and eliminate RNase H activity of the pol |
| 6448386 |
High molecular weight major outer membrane protein of moraxella |
September 10, 2002 |
| An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications an |
| 6444444 |
Genes encoding mycobacterial proteins associated with cell binding and cell entry and uses there |
September 3, 2002 |
| A gene from a strain of Mycobacterium encoding a protein of molecular weight between about 45 to about 60 kDa and associated with cell binding and cell entry was cloned. The genes and encoded protein have utility in immunogenic preparations or diagnostic applications. |
| 6440701 |
Transferrin receptor genes of Moraxella |
August 27, 2002 |
| Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor |
| 6440425 |
High molecular weight major outer membrane protein of moraxella |
August 27, 2002 |
| An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications an |
| 6440424 |
High molecular weight major outer membrane protein of moraxella |
August 27, 2002 |
| An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, has a molecular mass of about 200 kDa. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic |
| 6437096 |
Transferrin receptor of moraxella |
August 20, 2002 |
| Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor |
| 6432669 |
Protective recombinant Haemophilus influenzae high molecular weight proteins |
August 13, 2002 |
| Protective high molecular weight (HMW) proteins are produced recombinantly by expression from E. coli by using a promoter effective in E. coli and a nucleic acid molecule which contains a modified operon of a non-typeable strain of Haemophilus. The modified operon contains the portion on |
| 6403081 |
Attenuated strains of leishmania and uses thereof |
June 11, 2002 |
| Attenuated strains of Leishmania are provided in which at least one gene contributing to virulence of the strain and expressed in both the promastigote and amastigote forms of the strain is functionally disabled, such as, by deleting at least a portion of the gene or by mutagenesis of |
| 6399076 |
Acellular pertussis vaccines and methods of preparation thereof |
June 4, 2002 |
| Acellular pertussis vaccines comprise purified toxin or toxoid thereof, filamentous haemagglutinin, pertactin and fimbrial agglutinogens formulated to confer protection to at least 70% of members of an at-risk population. The fimbrial agglutinogens may be prepared from a Bordetella s |
| 6395714 |
Expressing gp140 fragment of primary HIV-1 isolate |
May 28, 2002 |
| A vector for eliciting an immune response to a host comprising a gene encoding the gp140 protein of the primary isolate of HIV-1, BX08, under the control of a promotor for expression of the protein in the host, specifically plasmid pCMV.gp140.BX08. Murine and human MHC class 1-restri |
| 6395469 |
Inactivated respiratory syncytial viral vaccines |
May 28, 2002 |
| An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopot |
| 6391313 |
Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxell |
May 21, 2002 |
| A multi-valent immunogenic composition confers protection on an immunized host against infection caused by both Haemophilus influenzae and Moraxella catarrhalis. Such composition comprises at least four antigens comprising at least one antigen from Haemophilus influenzae, and at least on |
| 6368589 |
Use of autologous promoters to express gene products in Bordetella |
April 9, 2002 |
| Autologous promoters are used to effect expression of gene products in Bordetella strains. Hybrid Bordetella genes are constructed comprising a Bordetella gene, particularly one encoding a Bordetella antigen, fused at an ATG codon to a native but autologous Bordetella promoter or other |
| 6361779 |
Transferrin receptor genes |
March 26, 2002 |
| Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria norm |
